SCHEDULE 13G/A: Adage Capital Management Discloses 1.55% Passive Stake in Immunic, Inc.
Beneficial Ownership Disclosure
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 1.55% beneficial ownership stake in Immunic, Inc., holding 1,398,600 shares of common stock as of December 31, 2024.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Immunic, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 1,398,600 shares of Immunic, Inc. common stock.
- This ownership represents 1.55% of Immunic, Inc.'s outstanding common stock.
- The percentage is calculated based on 90,079,016 shares of common stock outstanding as of October 31, 2024, as reported in Immunic, Inc.'s Quarterly Report for the quarter ended September 30, 2024.
- The Reporting Persons hold these shares with shared voting power and shared dispositive power.
- The acquisition and holding of these securities are stated to be in the ordinary course of business and not for the purpose of changing or influencing control of Immunic, Inc.
Sentiment
Score: 5
Explanation: Neutral. The document is a routine beneficial ownership disclosure, indicating a passive stake by an institutional investor. It provides no positive or negative operational or financial news about the issuer.
Positives
- A notable institutional investor, Adage Capital Management, maintains a stake in Immunic, Inc., indicating continued institutional interest.
- The filing confirms the investment is for ordinary course of business, not for activist purposes, which can signal stability for the company's management.
Future Outlook
The document is a beneficial ownership filing and does not contain forward-looking statements or guidance regarding Immunic, Inc.'s future operations or financial performance.
Industry Context
This Schedule 13G filing indicates a passive investment by Adage Capital Management in Immunic, Inc. It does not provide specific industry context or trends, but generally, institutional investments like this reflect a fund's portfolio allocation strategy within the broader market.
Comparison to Industry Standards
- This document is a beneficial ownership filing and does not provide information suitable for comparison to industry standards regarding company performance, projects, or results. It focuses solely on the ownership stake of a specific investment firm.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can be a minor positive signal of institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which 90,079,016 shares of Common Stock outstanding were reported in Immunic, Inc.'s Quarterly Report for the quarter ended September 30, 2024. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership determination date). |
| 2025-02-12 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
Immunic Inc, Adage Capital Management, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.